(Q36840119)

English

Expression of urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in benign, borderline, malignant primary and metastatic ovarian tumors

scientific article published on December 1996

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

16 August 2017

Expression of urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in benign, borderline, malignant primary and metastatic ovarian tumors (English)

1 reference

Europe PubMed Central

PubMed publication ID

16 August 2017

1 reference

based on heuristic

inferred from title

author name string

M E van der Burg

1

1 reference

Europe PubMed Central

PubMed publication ID

16 August 2017

S C Henzen-Logmans

2

1 reference

Europe PubMed Central

PubMed publication ID

16 August 2017

E M Berns

3

1 reference

Europe PubMed Central

PubMed publication ID

16 August 2017

W L van Putten

4

1 reference

Europe PubMed Central

PubMed publication ID

16 August 2017

J G Klijn

5

1 reference

Europe PubMed Central

PubMed publication ID

16 August 2017

J A Foekens

6

1 reference

Europe PubMed Central

PubMed publication ID

16 August 2017

language of work or name

0 references

publication date

1 December 1996

1 reference

Europe PubMed Central

PubMed publication ID

16 August 2017

number of pages

5

1 reference

based on heuristic

inferred from page(s)

International Journal of Cancer

1 reference

Europe PubMed Central

PubMed publication ID

16 August 2017

69

1 reference

Europe PubMed Central

PubMed publication ID

16 August 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

16 August 2017

475-479

1 reference

Europe PubMed Central

PubMed publication ID

16 August 2017

Prognostic value of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in breast carcinomas

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0215%2819961220%2969%3A6%3C475%3A%3AAID-IJC10%3E3.0.CO%3B2-0

21 January 2018

Urokinase-type plasminogen activator and its inhibitor PAI-1: predictors of poor response to tamoxifen therapy in recurrent breast cancer

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0215%2819961220%2969%3A6%3C475%3A%3AAID-IJC10%3E3.0.CO%3B2-0

21 January 2018

Plasminogen activator inhibitor-1 and prognosis in primary breast cancer

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0215%2819961220%2969%3A6%3C475%3A%3AAID-IJC10%3E3.0.CO%3B2-0

21 January 2018

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0215%2819961220%2969%3A6%3C475%3A%3AAID-IJC10%3E3.0.CO%3B2-0

21 January 2018

Randomized trial comparing two combination chemotherapy regimens (CHAP-5 v CP) in advanced ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0215%2819961220%2969%3A6%3C475%3A%3AAID-IJC10%3E3.0.CO%3B2-0

21 January 2018

A ligand-free, soluble urokinase receptor is present in the ascitic fluid from patients with ovarian cancer.

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0215%2819961220%2969%3A6%3C475%3A%3AAID-IJC10%3E3.0.CO%3B2-0

21 January 2018

Clinical relevance of the urokinase-type and tissue-type plasminogen activators and of their type 1 inhibitor in breast cancer

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0215%2819961220%2969%3A6%3C475%3A%3AAID-IJC10%3E3.0.CO%3B2-0

21 January 2018

Immunological identity of urokinase and ovarian carcinoma plasminogen activator released in tissue culture

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0215%2819961220%2969%3A6%3C475%3A%3AAID-IJC10%3E3.0.CO%3B2-0

21 January 2018

Plasminogen activators and plasminogen activator inhibitors in blood and tumour fluids of patients with ovarian cancer

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0215%2819961220%2969%3A6%3C475%3A%3AAID-IJC10%3E3.0.CO%3B2-0

21 January 2018

Cell membrane receptors for urokinase plasminogen activator are increased in malignant ovarian tumours

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0215%2819961220%2969%3A6%3C475%3A%3AAID-IJC10%3E3.0.CO%3B2-0

21 January 2018

The significance of urokinase- type plasminogen activator, its inhibitors, and its receptor in ascites of patients with epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0215%2819961220%2969%3A6%3C475%3A%3AAID-IJC10%3E3.0.CO%3B2-0

21 January 2018

Urokinase-plasminogen activator, a marker for aggressive breast carcinomas. Preliminary report

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0215%2819961220%2969%3A6%3C475%3A%3AAID-IJC10%3E3.0.CO%3B2-0

21 January 2018

Urokinase (uPA) and PAI-1 predict survival in advanced ovarian cancer patients (FIGO III) after radical surgery and platinum-based chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0215%2819961220%2969%3A6%3C475%3A%3AAID-IJC10%3E3.0.CO%3B2-0

21 January 2018

The plasminogen-activation system in ovarian tumors

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0215%2819961220%2969%3A6%3C475%3A%3AAID-IJC10%3E3.0.CO%3B2-0

21 January 2018

Identifiers

10.1002/(SICI)1097-0215(19961220)69:6<475::AID-IJC10>3.0.CO;2-0

1 reference

Europe PubMed Central

PubMed publication ID

16 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

16 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36840119&oldid=1773710421"